Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase

Authors

Uffe H. Olesen, Rigshospitalet
Jakob G. Petersen, Rigshospitalet
Antje Garten, University of Leipzig
Wieland Kiess, University of Leipzig
Jun Yoshino, Washington University School of Medicine
Shin-Ichiro Imai, Washington University School of MedicineFollow
Mette K. Christensen, TopoTarget A/S
Peter Fristrup, Technical University of Denmark
Annemette V. Thougaard, TopoTarget A/S
Fredrik Björkling, TopoTarget A/S
Peter B. Jensen, TopoTarget A/S
Søren J. Nielsen, TopoTarget A/S
Maxwell Sehested, Rigshospitalet

Journal

BMC Cancer

Publication Date

2010

Volume

10

Inclusive Pages

677

Document Type

Open Access Publication

Rights and Permissions

Olesen et al. BMC Cancer 2010, 10:677 http://www.biomedcentral.com/1471-2407/10/677

Recommended Citation

Olesen, Uffe H.; Petersen, Jakob G.; Garten, Antje; Kiess, Wieland; Yoshino, Jun; Imai, Shin-Ichiro; Christensen, Mette K.; Fristrup, Peter; Thougaard, Annemette V.; Björkling, Fredrik; Jensen, Peter B.; Nielsen, Søren J.; and Sehested, Maxwell, "Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase." BMC Cancer. 10, 677. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/53